STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more

<iframe
  src="https://statesidedaily.com/embed/cluster/5e2bb97182e43c081a625a43903e53ec9e03a7ca"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more"></iframe>